Historically, covalent inhibitors were avoided due to toxic side effects, but the latest breakthroughs in targeting have created a new landscape of opportunities. New breakthrough drugs like ibrutinib, sotorasib, and afatinib are reshaping the landscape of covalent inhibitors. For leaders of R&D, this idea in brief highlights key players, forces, and publication trends that enable better navigation of the opportunities ahead.
![fanned image](https://cdn.prod.website-files.com/650867962272bf8f15c1034b/65661bf41c7b81419417f8fe_INSGENENGWHP101675-Covalently-Linked-Inhibitors-Executive-Summary-Fanned%2520image.png)